1. Expression profiling of muscle invasive and non-invasive bladder tumors for biomarkers identification related to drug resistance, sensitivity and tumor progression
   Olga Antonova et al, 2020, Biotechnology & Biotechnological Equipment CrossRef
2. NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways
   Bihui Li et al, 2022, Frontiers in Pharmacology CrossRef
3. Metabolite identification and pharmacokinetic profiling of PP242, an ATP-competitive inhibitor of mTOR using ultra high-performance liquid chromatography and mass spectrometry
   Md. Mamunur Rashid et al, 2018, Journal of Chromatography B CrossRef
4. mTORC2: A neglected player in aging regulation
   Weitong Xu et al, 2024, Journal of Cellular Physiology CrossRef
5. Ras-mediated activation of mTORC2 promotes breast epithelial cell migration and invasion
   Shannon E. Collins et al, 2023, Molecular Biology of the Cell CrossRef
6. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study
   Joaquim Bellmunt et al, 2024, Clinical Genitourinary Cancer CrossRef
7. Evaluation of the antitumor effects of PP242 in a colon cancer xenograft mouse model using comprehensive metabolomics and lipidomics
   Md Mamunur Rashid et al, 2020, Scientific Reports CrossRef